ATNM

Actinium Pharmaceuticals (ATNM)

Actinium Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:ATNM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/11/28	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/18	22 : 00	PR Newswire (US)	Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/15	06 : 57	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/09	08 : 51	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/06	21 : 30	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/06	07 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/06	07 : 10	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/06	07 : 05	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/06	07 : 00	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/11/04	21 : 30	PR Newswire (US)	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/09/20	21 : 00	PR Newswire (US)	Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/08/06	06 : 15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/08/05	20 : 30	Edgar (US Regulatory)	Form 8-K - Current report	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/08/05	20 : 00	PR Newswire (US)	Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/08/01	21 : 00	PR Newswire (US)	Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/07/25	21 : 45	PR Newswire (US)	Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/07/25	20 : 30	PR Newswire (US)	Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/06/17	21 : 00	PR Newswire (US)	Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/06/14	21 : 30	PR Newswire (US)	Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/06/11	21 : 30	PR Newswire (US)	Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/06/10	21 : 30	PR Newswire (US)	Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/05/15	21 : 30	PR Newswire (US)	Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/05/15	07 : 38	PR Newswire (US)	Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phas	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/05/13	21 : 30	PR Newswire (US)	Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/05/07	21 : 00	PR Newswire (US)	Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/04/18	21 : 00	PR Newswire (US)	Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/04/01	21 : 00	PR Newswire (US)	Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/03/26	20 : 18	PR Newswire (US)	Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/03/11	20 : 30	PR Newswire (US)	Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand	AMEX:ATNM	Actinium Pharmaceuticals Inc
2024/02/26	21 : 30	PR Newswire (US)	Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings \| Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT	AMEX:ATNM	Actinium Pharmaceuticals Inc